| 摘要: |
| 目的 探讨人源脐带间充质干细胞（hUc-MSCs）治疗大鼠佐剂骨关节炎（OA）的价值。 方法 将 42 只大鼠按抽签 法分为 7 组，G 组为正常对照组，其余 6 组进行右后肢膝关节注射 0.1%碘乙酸 0.1ml 造模；A 组造模后第 6 周处死（空白对照）；B 组 造模后第 6 周注射 0.9%氯化钠溶液，第 10 周处死；C 组造模后第 6、8 周 2 次注射 0.9%氯化钠溶液，第 12 周处死；D 组造模后第 6 周 1 次关节腔注射 hUc-MSCs，第 10 周处死；E 组造模后第 6、8 周 2 次关节腔注射 hUc-MSCs，第 12 周处死；F 组造模后第 6、8 周 2 次尾静脉注射 hUc-MSCs，第 12 周处死；各组大鼠造模前后和注射后测定关节肿胀度和疼痛评分；处死后取关节组织病理检查。 结果 D、E 组较 B、C 组的关节肿胀度均有减小，E 组的消肿作用更显著；而 F 组的消肿作用不明显；D、E 组关节疼痛评分较 B、C 组 均有缓解，E 组止痛作用更显著；F 组的止痛作用与 E 组相当。Mankin 关节软骨病理分级积分结果提示：D 组与 B 组比较无统计学差 异；F 组低于 C 组；而 E 组低于 F 组。病理检查提示：A 组造模后第 6 周关节组织病理检查类似于 OA 病理表现，无宿主与移植物的相 互排斥反应发生；B 组表现类似 A 组，C 组关节病理破坏较 B 组重；D 组滑膜重度增生侵入关节腔，炎症细胞浸润，其病理破坏较 A 组 重，较 C 组轻，并且软骨染色较浅；E 组滑膜增生和炎症较 D 组轻，软骨染色较 D 组更浅；F 组关节病理表现与 E 组基本相仿；在饲养、 造模、注射、观察的实验过程中，无明显局部或者全身的宿主与移植物相互排斥反应发生，未发现注射部位、关节感染、坏死等不良反 应，无意外疾病和死亡发生。 结论 2 次关节腔注射和尾静脉注射 hUc-MSCs 均能较好缓解碘乙酸佐剂 OA 的疼痛，改善滑膜炎症， 修复软骨等作用，而且 2 次关节腔注射 hUc-MSCs 能更明显能消除关节肿胀，减轻滑膜炎症和软骨损害的病理改变；无明显的不良反 应发生；hUc-MSCs 治疗 OA 具有良好的有效性和安全性。 |
| 关键词: 人源脐带间充质干细胞 佐剂 骨关节炎 实验性 移植注射 |
| DOI： |
| 分类号: |
| 基金项目:湖州市生物医药重大专项计划 |
|
| Human umbilical cord-derived mesenchymal stem cells implantation in treatment of rat adjuvant arthritis |
|
JIANG Feng,YANG Xiaobing,ZHANG Fan,SHOU Qiyang,XU Zhiguo
|
|
Huzhou Third Municipal Hospita
|
| Abstract: |
| Objective To investigate the efficacy of human umbilical cord-derived mesenchymal stem cells (hUc-MSCs) implantation in treatment of rat adjuvant arthritis. Methods Forty two rats were randomly divided into 7 groups with 6 animals in each. Acetic acid was injected in right hind joint to induce the arthritis in groups A, B, C, D, E, F；group G served as blank control group. Rats in groupA were sacrificed at wk 6 after the model was made (model group), rats in group B were injected with normal saline at wk 6 and sacrificed at wk 10; rates in group C were injected with normal saline at wk 6, 8 and sacrificed at wk 12; rats in group D were injected with hUc-MSCs in articular cavity at wk 6 and sacrificed at wk 10; rats in group E were injected with hUc-MSCs in articular cavity at wk 6, 8 and sacrificed at wk 12; rats in group F were injected with hUc-MSCs through tail vein at wk 6, 8 and sacrificed at wk 12. The swelling degree and pain degree of rats before and after model made and before and after treatment were evaluated. Pathological examinations in joints were performed after sacrifice. Results Compared with groups B and C, the joint swelling degree of group D and E was reduced and that of group E were significantly reduced while the change of group F was not significant. Compared with groups B and C, the average pain scores of group D and E were reduced and the analgesic effect in group E and F was more significant. The result of the pathological grades of Mankin articular cartilage showed that there was no difference between group D and group B, that of group F was better than group C while that of group E was better than group F. The pathological examination at wk 6 in groups A and B showed the manifestations of osteoarthritis and no graft rejection responses. In group D, the proliferated synovial membrane invading the aricular cavity with infiltration of inflammatory cells, the pathological damage was more severe than that of group A, but lighter than group C. The synovial proliferation and inflammation in group E was lighter than that in group D, and cartilage staining was more shallow than that in group D. The pathological damage of group F was similar to that in group E. Conclusion The injection of hUc-MSCs in joint or in tail vein can release joint pain of osteoarthritis, improve synovitis, and repair cartilage damage, suggesting that hUc-MSCs im- plantation is effective and safe for treatment of osteoarthritis in rats. |
| Key words: hUc-MSCs Adjuvant Osteoarthritis Experimental Implatation |
